Compare Tango Therapeutics Inc. (TNGX) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Advanced Drainage Systems Inc — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Advanced Drainage Systems Inc trades at $125.03 (market cap $9.56B). The key difference: Advanced Drainage Systems Inc is far larger — about 2.5× Tango Therapeutics Inc.'s market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Advanced Drainage Systems Inc for 43 Days on average.
| TNGX | WMS | |
|---|---|---|
Market Cap | $3.75B | $9.56B |
Volume | 9,619,106 | 716,757 |
Sector | Health | Basic Materials |
52-Week High | $32.90 | $175.38 |
52-Week Low | $7.50 | $125.19 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $2.77B | $11.16B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Advanced Drainage Systems (WMS) trades at $125.19, down 0.59% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.49 beating estimates of $2.10. Revenue remains stable at $2.90B for 2025, while profitability metrics show robust ROE of 24.9% and net margin of 14%. Recent news highlights institutional buying activity and the release of Q1 2027 results showing 21% revenue growth.
WMS presents a compelling investment case with strong fundamentals and analyst consensus pointing to significant upside potential (target $188.20). However, near-term technical weakness and projected negative cash flow in 2026 warrant caution. The stock offers exposure to water infrastructure growth but faces execution risks from recent acquisitions and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
